<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546273</url>
  </required_header>
  <id_info>
    <org_study_id>FA/MI/01</org_study_id>
    <secondary_id>EudraCT Number: 2006-000690-29</secondary_id>
    <nct_id>NCT00546273</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Phase I Study, to Study the Tolerability and Immunogenicity of 4 RUTI Antituberculous Vaccine Different Doses (5, 25, 100 y 200µg of FCMtb) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archivel Farma S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety of a new vaccine against Tuberculosis (RUTI)
      when administered to healthy adult volunteers, compared to placebo; and determine its safe
      dosage range. An initial evaluation of immune responses to the vaccine compared to placebo
      will also be undertaken.

      In the present Phase I clinical trial, four increasing doses of RUTI will be tested, the
      groups composed by 6 volunteers each. (Total of 24 volunteers). The escalation to a new dose
      to test will be done after the safety of the previous dose has been ensured.

      For each dose of FCMtb to test, each volunteer will be inoculated twice (at day 0 and day 28)
      with RUTI (4 volunteers) or placebo (2 volunteers) and will be followed-up up to 25 weeks
      from the first inoculation. The global length of the study will be approximately 15 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RUTI is a therapeutic vaccine made from virulent M.tuberculosis bacteria, grown in stressful
      conditions, fragmented, detoxified, heat inactivated (FCMtb) and liposomed. RUTI provides a
      strong humoral and cellular immune response against antigens from active growing and latent
      bacilli but also against structural antigens, as it has been proved in animal models of
      latent tuberculosis infection. The vaccine has been designed to be used against Latent
      Tuberculosis Infection as a therapeutic vaccine after 1-month of chemotheraputic treatment,
      instead the current treatment based on 6-9 months of chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Pain Score (Visual Analogic Scale, That Ranges From 0 to 100) to Evaluate Each Volunteer Subjective Pain Intensity at the Inoculation Point</measure>
    <time_frame>at protocol defined timepoints: days 0, 1, 3, 7, 21, 28, 29, 31, 35, 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, Intensity and Relationship to Vaccination of Local and Systemic Events</measure>
    <time_frame>during the whole study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Clinically Relevant Abnormalities in the Laboratory Tests According to the Doctors' Impression</measure>
    <time_frame>at protocol defined timepoints: days 0, 7, 21, 28, 35, 56, 112 &amp; 156</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Immunogenicity of the Different Doses of the Vaccine Tested</measure>
    <time_frame>at protocol defined timepoints: days 0, 7, 21, 28, 35, 56, 112 &amp; 156</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Latent Tuberculosis Infection</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>RUTI 5 micrograms of FCMtb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RUTI dose: 5 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 25 micrograms of FCMtb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RUTI dose: 25 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 100 micrograms of FCMtb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RUTI dose: 100 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUTI 200 micrograms of FCMtb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RUTI 200 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of the vaccine RUTI (total n=8, n=2 for each period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI</intervention_name>
    <description>dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28</description>
    <arm_group_label>RUTI 5 micrograms of FCMtb</arm_group_label>
    <other_name>FCMtb is the active compound of the vaccine RUTI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI</intervention_name>
    <description>dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28</description>
    <arm_group_label>RUTI 25 micrograms of FCMtb</arm_group_label>
    <other_name>FCMtb is the active compound of the vaccine RUTI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI</intervention_name>
    <description>dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28</description>
    <arm_group_label>RUTI 100 micrograms of FCMtb</arm_group_label>
    <other_name>FCMtb is the active compound of the vaccine RUTI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI</intervention_name>
    <description>dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28</description>
    <arm_group_label>RUTI 200 micrograms of FCMtb</arm_group_label>
    <other_name>FCMtb is the active compound of the vaccine RUTI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo of the vaccine RUTI</intervention_name>
    <description>placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Healthy, based on medical examination at inclusion

          -  Male Caucasian subjects, aged between 18 and 40 years

          -  Willing and likely to be able to comply with the trial procedures

        Exclusion Criteria:

          -  Evidence of previous, current or latent tuberculosis, as radiological findings on
             chest X ray compatible with previous or current infection with tuberculosis

          -  Positive T-SPOT TB result

          -  BCG-vaccinated subjects

          -  History of severe organ-system diseases, including

          -  History of allergic disorders or known hypersensitivity to any drug or vaccine, or to
             any of the vaccine to be studied components

          -  Personal or familiar history of autoimmune diseases, or Positive Antinuclear
             Antibodies

          -  HIV, HBV and HCV sero-positive

          -  Suspected or known current drug and/or alcohol abuse (as defined by an alcohol intake
             of &gt; 50 g a day

          -  Lost of more than 400 mL of blood within 12 weeks, or more than 250 mL within 4 weeks,
             before the recruitment

          -  Laboratory parameters outside of normal ranges considered clinically significant

          -  Intake of trial medication in other clinical trials within 1 month of the first
             vaccination

          -  Intake of any other drugs that could not be eliminated of the body before the first
             vaccination, especially anti-inflammatory nonsteroid and corticosteroid drugs

          -  Acute disease with &gt; 37ºC temperature within 72 hours before the first vaccination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere-Joan Cardona, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unitat de Tuberculosi Experimental. Fundació Institut per la Investigació en Ciències de la Salut Germans Trias i Pujol.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Costa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmacology Department. Hospital Universitari &quot;Germans Trias i Pujol&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Experimental Tuberculosis Unit. Fundació Institut per la Investigació Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Department. Hospital Universitari Germans Trias i Pujol.</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.germanstrias.org/</url>
    <description>Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol homepage</description>
  </link>
  <reference>
    <citation>Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, Vilaplana C, Tapia G, Ausina V. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005 Feb 3;23(11):1393-8.</citation>
    <PMID>15661388</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ, Amat I. [Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection]. Arch Bronconeumol. 2006 Jan;42(1):25-32. Review. Spanish.</citation>
    <PMID>16426520</PMID>
  </reference>
  <reference>
    <citation>Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006 May-Jul;86(3-4):273-89. Epub 2006 Mar 20. Review.</citation>
    <PMID>16545981</PMID>
  </reference>
  <reference>
    <citation>Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montané E, Singh M, Spallek R, Ausina V, Cardona PJ. The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand J Immunol. 2008 Jun;67(6):610-7. doi: 10.1111/j.1365-3083.2008.02103.x. Epub 2008 Apr 4.</citation>
    <PMID>18397200</PMID>
  </reference>
  <reference>
    <citation>Guirado E, Gil O, Cáceres N, Singh M, Vilaplana C, Cardona PJ. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol. 2008 Aug;15(8):1229-37. doi: 10.1128/CVI.00094-08. Epub 2008 Jun 4.</citation>
    <PMID>18524883</PMID>
  </reference>
  <reference>
    <citation>Gil O, Vilaplana C, Guirado E, Díaz J, Cáceres N, Singh M, Cardona PJ. Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse. Clin Vaccine Immunol. 2008 Nov;15(11):1742-4. doi: 10.1128/CVI.00255-08. Epub 2008 Sep 30.</citation>
    <PMID>18827194</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <results_first_submitted>October 31, 2008</results_first_submitted>
  <results_first_submitted_qc>March 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2009</results_first_posted>
  <last_update_submitted>May 14, 2009</last_update_submitted>
  <last_update_submitted_qc>May 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pere-Joan Cardona</name_title>
    <organization>Fundacio Institut Germans Trias i Pujol</organization>
  </responsible_party>
  <keyword>LTBI (Latent tuberculosis infection)</keyword>
  <keyword>TB(Tuberculosis)</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Four RUTI doses were tested, in a sequencial way (n=6 each). 14 days before starting each level of treatment, subjects, after signing the informed consent, were screened in the Phase 1 Unit (Hospital Germans Trias i Pujol) in order to decide if they were elegible to be part of the study.</recruitment_details>
      <pre_assignment_details>24 volunteers were enrolled and distributed in 4 groups, one group for every period (each period: 6 new volunteers). There was one period per dose tested, and doses were tested increasingly, not beginning to test one dose until clinically ensured the safety of the previous dose. The double blind was opened at the end of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RUTI 5 Micrograms of FCMtb</title>
          <description>RUTI dose: 5 micrograms of FCMtb</description>
        </group>
        <group group_id="P2">
          <title>RUTI 25 Micrograms of FCMtb</title>
          <description>RUTI dose: 25 micrograms of FCMtb</description>
        </group>
        <group group_id="P3">
          <title>RUTI 100 Micrograms of FCMtb</title>
          <description>RUTI dose: 100 micrograms of FCMtb</description>
        </group>
        <group group_id="P4">
          <title>RUTI 200 Micrograms of FCMtb</title>
          <description>RUTI dose: 200 micrograms of FCMtb</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>placebo of the vaccine RUTI, given subcutaneously twice, on days 0 and 28</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>III</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>IV</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RUTI 5 Micrograms of FCMtb</title>
          <description>RUTI dose: 5 micrograms of FCMtb</description>
        </group>
        <group group_id="B2">
          <title>RUTI 25 Micrograms of FCMtb</title>
          <description>RUTI dose: 25 micrograms of FCMtb</description>
        </group>
        <group group_id="B3">
          <title>RUTI 100 Micrograms of FCMtb</title>
          <description>RUTI dose: 100 micrograms of FCMtb</description>
        </group>
        <group group_id="B4">
          <title>RUTI 200 Micrograms of FCMtb</title>
          <description>RUTI dose: 200 micrograms of FCMtb</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>placebo of the vaccine RUTI, given subcutaneously twice, on days 0 and 28</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.25" spread="2.87"/>
                    <measurement group_id="B2" value="26" spread="2.94"/>
                    <measurement group_id="B3" value="23" spread="2.16"/>
                    <measurement group_id="B4" value="22.25" spread="2.22"/>
                    <measurement group_id="B5" value="24" spread="4.75"/>
                    <measurement group_id="B6" value="24.08" spread="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VAS Pain Score (Visual Analogic Scale, That Ranges From 0 to 100) to Evaluate Each Volunteer Subjective Pain Intensity at the Inoculation Point</title>
        <time_frame>at protocol defined timepoints: days 0, 1, 3, 7, 21, 28, 29, 31, 35, 56</time_frame>
        <posting_date>11/2008</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Immunogenicity of the Different Doses of the Vaccine Tested</title>
        <description>Immunological assays are performed at all timepoints to determine vaccine immunogenicity</description>
        <time_frame>at protocol defined timepoints: days 0, 7, 21, 28, 35, 56, 112 &amp; 156</time_frame>
        <posting_date>11/2008</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Occurrence, Intensity and Relationship to Vaccination of Local and Systemic Events</title>
        <time_frame>during the whole study</time_frame>
        <posting_date>11/2008</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Clinically Relevant Abnormalities in the Laboratory Tests According to the Doctors' Impression</title>
        <description>haematological and biochemical laboratory tests</description>
        <time_frame>at protocol defined timepoints: days 0, 7, 21, 28, 35, 56, 112 &amp; 156</time_frame>
        <population>All the participants of the study were analyzed for this specific outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>RUTI 5 Micrograms of FCMtb</title>
            <description>RUTI dose: 5 micrograms of FCMtb</description>
          </group>
          <group group_id="O2">
            <title>RUTI 25 Micrograms of FCMtb</title>
            <description>RUTI dose: 25 micrograms of FCMtb</description>
          </group>
          <group group_id="O3">
            <title>RUTI 100 Micrograms of FCMtb</title>
            <description>RUTI dose: 100 micrograms of FCMtb</description>
          </group>
          <group group_id="O4">
            <title>RUTI 200 Micrograms of FCMtb</title>
            <description>RUTI dose: 200 micrograms of FCMtb</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo of the vaccine RUTI, given subcutaneously twice, on days 0 and 28</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinically Relevant Abnormalities in the Laboratory Tests According to the Doctors' Impression</title>
          <description>haematological and biochemical laboratory tests</description>
          <population>All the participants of the study were analyzed for this specific outcome measure.</population>
          <units>number of abnormalities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure of the results has to be previously arranged if mutually agreeable to both investigators and the company manufacturer of the vaccine RUTI: Archivel Farma S.L.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cristina Vilaplana, MD</name_or_title>
      <organization>UTE. Fund. Inst. Germans Trias i Pujol</organization>
      <phone>+34 93 497 86 81</phone>
      <email>cvilaplana@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

